OVID - オ―ビッド・セラピュ―ティクス (Ovid Therapeutics Inc.) オ―ビッド・セラピュ―ティクス

 OVIDのチャート


 OVIDの企業情報

symbol OVID
会社名 Ovid Therapeutics Inc (オ―ビッド・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オービッド・セラピューティクス(Ovid Therapeutics Inc.)はバイオ医薬品企業。同社はまれな神経学的障害患者ための医薬品の開発に従事する。同社のリード薬剤候補はOV101で、第2のリードドラッグ候補はOV935である。OV101(ガボクサドール)はデルタ選択的なGABAA受容体作用薬である。同社が潜在的に持続性抑制を回復させ、障害症状を緩和するために、アンジェルマン症候群と脆弱X症候群に応用するOV101は現在開発中である。同社はアンジェルマン症候群の成人でOV101の第II相STARS試験とアンジェルマン症候群または脆弱X症候群の若者でPhase I試験を開始した。同社は武田薬品工業と協力して、まれなてんかん性脳症の治療薬OV935を開発する。   オ―ビッド・セラピュ―ティクスは米国のバイオ医薬品企業。主に中枢神経系疾患の治療薬の開発を行う。候補薬には、アンジェルマン症候群及び脆弱X症候群を対象とした「OV101」、そしてドラベ症候群、レノックス・ガスト―症候群、結節性硬化症などの希少てんかん性脳症を対象とする「OV935」(TAK-935)がある。本社はニューヨーク。   Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represents a substantial opportunity medically and commercially. Based on recent scientific advances in genetics and the biological pathways of the brain, Ovid aims to identify, discover and acquire novel compounds for the treatment of rare neurological disorders. Ovid has built a deep knowledge of such disorders, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders. As a result of this knowledge, Ovid has developed a robust pipeline of first-in-class compounds and programs. The company continues to execute on its strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions. These pipeline programs include programs targeting rare epilepsies, Angelman syndrome and Fragile X syndrome, as well as early-stage programs into other monogenetic disorders. Ovid's most advanced pipeline programs include OV935 (soticlestat) in collaboration with Takeda and OV101 a δ-selective GABAA receptor agonist. Ovid's emerging pipeline programs include OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorder; and other non-disclosed researched targets.
本社所在地 1460 Broadway Suite 15044 New York NY 10036 USA
代表者氏名 Jeremy Max Levin ジェレミーマックスレビン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 646-661-7661
設立年月日 41730
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.ovidrx.com
nasdaq_url https://www.nasdaq.com/symbol/ovid
adr_tso
EBITDA EBITDA(百万ドル) -46.99967
終値(lastsale) 5.99
時価総額(marketcap) 147545554.21
時価総額 時価総額(百万ドル) 151.73300
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 89.13840
当期純利益 当期純利益(百万ドル) -36.89227
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ovid Therapeutics Inc revenues was not reported. Net loss decreased 41% to $26.1M. Lower net loss reflects Research and development decrease of 56% to $16.6M (expense) Interest income increase from $63K to $522K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.18 to -$1.06.

 OVIDのテクニカル分析


 OVIDのニュース

   Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Northern Trust Corp  2021/12/03 09:22:41 Transcript Daily
Northern Trust Corp trimmed its stake in Ovid Therapeutics Inc. (NASDAQ:OVID) by 83.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 82,052 shares of the companys stock after selling 399,811 shares during the quarter. Northern Trust Corps holdings in Ovid Therapeutics were worth $321,000 as of its []
   Ovid Therapeutics Inc. (NASDAQ:OVID) Short Interest Down 39.2% in November  2021/11/30 09:40:41 Transcript Daily
Ovid Therapeutics Inc. (NASDAQ:OVID) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 663,000 shares, a drop of 39.2% from the October 31st total of 1,090,000 shares. Based on an average trading volume of 242,700 shares, the days-to-cover ratio is []
   Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $9.13  2021/11/24 14:34:41 Dakota Financial News
Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) have been given a consensus rating of Hold by the nine research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among analysts []
   Ovid Therapeutics (NASDAQ:OVID) Lifted to Buy at Zacks Investment Research  2021/11/21 10:38:41 Dakota Financial News
Zacks Investment Research upgraded shares of Ovid Therapeutics (NASDAQ:OVID) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. The firm currently has $4.00 target price on the stock. According to Zacks, Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with []
   Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions  2021/04/19 13:16:52 Benzinga
Ovid Therapeutics Inc (NASDAQ: OVID ) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The company says that while OV101 was well tolerated, with no significant safety signals observed, the company believes that efficacy outcomes observed in these trials do not support its further development. Now, the company … Full story available on Benzinga.com
   Riassunto: Takeda si assicura i diritti globali da Ovid Therapeutics per sviluppare e commercializzare soticlestat per il trattamento di bambini e adulti affetti da sindrome di Dravet e sindrome di Lennox-Gastaut  2021/03/04 01:08:00 Business Wire
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) e Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), una società biofarmaceutica imp
   Samenvatting: Takeda verzekert wereldwijde rechten van Ovid Therapeutics om Soticlestat te ontwikkelen en te commercialiseren voor de behandeling van kinderen en volwassenen met het syndroom van Dravet en het syndroom van Lennox-Gastaut  2021/03/03 14:54:00 Business Wire
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) en Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovidius”), een biofarmaceutisch bedrijf dat zich voor het ontwikkelen van geneesmiddelen die het leven van mensen met zeldzame neurologische aandoeningen veranderen, kondigde vandaag aan dat Takeda een exclusieve overeenkomst is aangegaan waarbij Takeda bij sluiting van Ovidius wereldwijde rechten zal verwerven om de onderzoeksgeneeskunde soti
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   Riassunto: Takeda si assicura i diritti globali da Ovid Therapeutics per sviluppare e commercializzare soticlestat per il trattamento di bambini e adulti affetti da sindrome di Dravet e sindrome di Lennox-Gastaut  2021/03/04 01:08:00 Business Wire
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) e Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), una società biofarmaceutica imp
   Samenvatting: Takeda verzekert wereldwijde rechten van Ovid Therapeutics om Soticlestat te ontwikkelen en te commercialiseren voor de behandeling van kinderen en volwassenen met het syndroom van Dravet en het syndroom van Lennox-Gastaut  2021/03/03 14:54:00 Business Wire
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) en Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovidius”), een biofarmaceutisch bedrijf dat zich voor het ontwikkelen van geneesmiddelen die het leven van mensen met zeldzame neurologische aandoeningen veranderen, kondigde vandaag aan dat Takeda een exclusieve overeenkomst is aangegaan waarbij Takeda bij sluiting van Ovidius wereldwijde rechten zal verwerven om de onderzoeksgeneeskunde soti
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréquence des crises chez les enfants atteints du syndrome de Dravet ou du syndrome de Lennox-Gastaut  2020/08/26 22:23:00 Business Wire
NEW YORK & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique s'engageant à développer des médicaments qui transforment la vie des personnes atteintes de maladies neurologiques rares, annoncent ce jour des résultats positifs de l'étude ELEKTRA de Phase 2 randomisée évaluant soticlestat chez des enfants atteints du syndrome de Dravet (SD) ou du syndrome de Lennox-Gast

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オ―ビッド・セラピュ―ティクス OVID Ovid Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)